Clinical impact of recent surge in acute parvovirus B19 infections in Leicester UK, March-July 2024

Affiliations

¹ Department of Paediatric Haematology, University Hospitals of Leicester NHS Trust, Leicester, UK.
² Department of Adult Haematology, University Hospitals of Leicester NHS Trust, Leicester, UK.
³ Department of Fetal Medicine Unit, University Hospitals of Leicester NHS Trust, Leicester, UK.
⁴ Department of Paediatric Emergency, University Hospitals of Leicester NHS Trust, Leicester, UK.
⁵ Department of Paediatrics, University Hospitals of Leicester NHS Trust, Leicester, UK.
⁶ Department of Nephrology and Transplant, University Hospitals of Leicester NHS Trust, Leicester, UK.
⁷ Department of Clinical Microbiology, University Hospitals of Leicester NHS Trust, Leicester, UK.
⁸ Department of Respiratory Sciences, University of Leicester, Leicester, UK.

Nabila Tabassum et al. J Med Virol. 2024 Sep.

. 2024 Sep;96(9):e29903.

doi: 10.1002/jmv.29903.

¹ Department of Paediatric Haematology, University Hospitals of Leicester NHS Trust, Leicester, UK.
² Department of Adult Haematology, University Hospitals of Leicester NHS Trust, Leicester, UK.
³ Department of Fetal Medicine Unit, University Hospitals of Leicester NHS Trust, Leicester, UK.
⁴ Department of Paediatric Emergency, University Hospitals of Leicester NHS Trust, Leicester, UK.
⁵ Department of Paediatrics, University Hospitals of Leicester NHS Trust, Leicester, UK.
⁶ Department of Nephrology and Transplant, University Hospitals of Leicester NHS Trust, Leicester, UK.
⁷ Department of Clinical Microbiology, University Hospitals of Leicester NHS Trust, Leicester, UK.
⁸ Department of Respiratory Sciences, University of Leicester, Leicester, UK.

No abstract available

References

1. d'Humières C, Fouillet A, Verdurme L, et al. An unusual outbreak of parvovirus B19 infections, France, 2023 to 2024. Euro Surveill. 2024;29(25):2400339. doi:10.2807/1560-7917.ES.2024.29.25.2400339
1. Nordholm AC, Trier Møller F, Fischer Ravn S, et al. Epidemic of parvovirus B19 and disease severity in pregnant people, Denmark, January to March 2024. Euro Surveill. 2024;29(24):2400299. doi:10.2807/1560-7917.ES.2024.29.24.2400299
1. European Centre for Disease Prevention and Control. Risks posed by reported increased circulation of human parvovirus B19 in the EU/EEA. 5 June 2024. https://www.ecdc.europa.eu/en/publications-data/risks-posed-reported-inc... (Accessed 15 July 2024)
1. Tang JW, Lau JSM, Wong SYN, et al. Dose‐by‐dose virological and hematological responses to intravenous immunoglobulin in an immunocompromised patient with persistent parvovirus B19 infection. J Med Virol. 2007;79(9):1401‐1405. doi:10.1002/jmv.20870
1. Crabol Y, Terrier B, Rozenberg F, et al. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus B19 infection: A retrospective study of 10 patients and review of the literature. Clin Infect Dis. 2013;56(7):968‐977. doi:10.1093/cid/cis1046